Research

Hormonal

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces significant weight loss (15-21%) in adults with obesity when administered weekly alongside lifestyle modifications.

If you have obesity or are overweight with related health issues, Tirzepatide is a once-weekly injection that works by mimicking hormones to reduce appetite and slow digestion. In clinical trials, patients lost 15-21% of their body weight over 72 weeks when combining the drug with diet and exercise. While nausea and diarrhea are common side effects, they affect a minority of users. This treatment is intended for long-term management, not short-term fixes.

GoodSupportsHIGH confidence
After 72 weeks, there was an average weight loss correlated with the Tirzepatide dose (5mg, 10mg, 15mg), resulting in 15%, 19.5%, and 20.9%, respectively. Meanwhile, the placebo group showed a weight loss of 3.1%.
Aleksandra Doryń et al. · Journal of Education Health and Sport · 2024

Why this rating

Based on Phase III clinical trials (SURMOUNT-1) with a large sample size (n=2539), though it is a review summarizing these trials rather than a primary data publication.

Source

Will Tirzepatide become a game-changer in the pharmacological treatment of obesity? - literature review

Aleksandra Doryń et al. · Journal of Education Health and Sport · 2024

DOI 10.12775/jehs.2024.71.49544

narrative_reviewCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →